Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 45

Related Articles by Review for PubMed (Select 19372552)

1.

HDAC2 regulates chromatin plasticity and enhances DNA vulnerability.

Marchion DC, Bicaku E, Turner JG, Schmitt ML, Morelli DR, Munster PN.

Mol Cancer Ther. 2009 Apr;8(4):794-801. doi: 10.1158/1535-7163.MCT-08-0985.

2.

Development of histone deacetylase inhibitors for cancer treatment.

Marchion D, M√ľnster P.

Expert Rev Anticancer Ther. 2007 Apr;7(4):583-98. Review.

PMID:
17428177
3.

Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis.

Shankar S, Srivastava RK.

Adv Exp Med Biol. 2008;615:261-98. doi: 10.1007/978-1-4020-6554-5_13. Review.

PMID:
18437899
4.

Histone deacetylase inhibitors in cancer therapy.

Rasheed WK, Johnstone RW, Prince HM.

Expert Opin Investig Drugs. 2007 May;16(5):659-78. Review.

PMID:
17461739
5.

Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics.

Hadnagy A, Beaulieu R, Balicki D.

Mol Cancer Ther. 2008 Apr;7(4):740-8. doi: 10.1158/1535-7163.MCT-07-2284. Review.

7.

Histone deacetylation: an important mechanism in inflammatory lung diseases.

Adcock IM, Ito K, Barnes PJ.

COPD. 2005 Dec;2(4):445-55. Review.

PMID:
17147010
8.

Chromatin acetylation status in the manifestation of neurodegenerative diseases: HDAC inhibitors as therapeutic tools.

Anne-Laurence B, Caroline R, Irina P, Jean-Philippe L.

Subcell Biochem. 2007;41:263-93. Review.

PMID:
17484132
9.

Histone deacetylases: target enzymes for cancer therapy.

Mottet D, Castronovo V.

Clin Exp Metastasis. 2008;25(2):183-9. Epub 2007 Dec 5. Review.

PMID:
18058245
10.

HDAC inhibitors and cancer therapy.

Atadja PW.

Prog Drug Res. 2011;67:175-95. Review.

PMID:
21141730
11.

Inhibition of histone deacetylation: a strategy for tumor radiosensitization.

Camphausen K, Tofilon PJ.

J Clin Oncol. 2007 Sep 10;25(26):4051-6. Review.

PMID:
17827453
12.

Histone deacetylase HDAC1/HDAC2-controlled embryonic development and cell differentiation.

Brunmeir R, Lagger S, Seiser C.

Int J Dev Biol. 2009;53(2-3):275-89. doi: 10.1387/ijdb.082649rb. Review.

13.
14.

The role of histone deacetylases (HDACs) in human cancer.

Ropero S, Esteller M.

Mol Oncol. 2007 Jun;1(1):19-25. doi: 10.1016/j.molonc.2007.01.001. Epub 2007 Mar 7. Review.

15.

Histone deacetylase inhibitors: a novel class of therapeutic agents in diabetic nephropathy.

Lee HB, Noh H, Seo JY, Yu MR, Ha H.

Kidney Int Suppl. 2007 Aug;(106):S61-6. Review.

16.

Explorative study on isoform-selective histone deacetylase inhibitors.

Suzuki T.

Chem Pharm Bull (Tokyo). 2009 Sep;57(9):897-906. Review.

17.
18.

Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase.

Barnes PJ, Ito K, Adcock IM.

Lancet. 2004 Feb 28;363(9410):731-3. Review.

PMID:
15001333
19.

HDAC's at work: everyone doing their part.

Peterson CL.

Mol Cell. 2002 May;9(5):921-2. Review.

PMID:
12049726
20.

The structure and function of histone deacetylases: the target for anti-cancer therapy.

Zhang Y, Fang H, Jiao J, Xu W.

Curr Med Chem. 2008;15(27):2840-9. Review.

PMID:
18991639
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk